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established in a low income country
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and Najmul Islam3
Abstract
Background: Diabetes registry enables practitioners to measure the characteristics and patterns of diabetes across
their patient population. They also provide insight into practice patterns which can be very effective in improving
care and preventing complications. The aim of this study was to assess the patterns, control levels and
complications at the baseline of the patients attending clinic at the large tertiary care hospital in Karachi, Pakistan
with the help of the registry. This can be used as a reference to monitor the control and also for a comparison
between peer groups.
Methods: This was a cross sectional study with the data obtained from diabetes registry collected with the help of
pre-designed questionnaire. HbA1c was used as a central diabetes measure and other related factors and
complications were assessed with it.
Results: Only 16.6% of the participants had optimal HbA1c≤ 7.0%. 52.9% of the patients were classified as having poor
control defined by HbA1c of >8%. Three fourth of the study population were obese according to Asian specific BMI
cutoffs and majority had type 2 diabetes with duration of diabetes ranging from less than one to about 35 years,
mean(SD) duration being 7.6 years (7.1). Overall only 4% of the patients were on combine target of HbA1c, LDL and BP.
Results of multivariable logistic regression showed that the odds of having optimal glycemic control increased by 3%
with every one year increase in age. In addition, having longer duration of diabetes was associated with 56% lower
odds of having good glycemic control. Moreover, having higher triglyceride levels was associated with 1% lower odds
of having good glycemic control.
Conclusion: This highlights the large burden of sub optimally controlled people with diabetes in Pakistani population,
a low income country with huge diabetes prevalence and ineffective primary health care system creating enormous
health and economic burden.
Background
The rapidly increasing burden of diabetes throughout
the world is alarming. According to the recent update by
the International Diabetes Federation (IDF) 415 million
adults have diabetes and this number is projected to
increase to 642 million by 2040 [1]. Among different
regions of the world, South Asia (SA) is found to have
very high prevalence of dysglycemia of around 43% [2].
Epidemiological data suggests that the prevalence of dia-
betes in SA has accelerated in the past two decades and
is mostly associated with the large scale urbanization
and industrialization [3, 4]. Increasing rates of over-
weight & obesity are among the important reasons for
rise in prevalence. The highest age-standardized preva-
lence in the region is estimated to be in Mauritius
(22.3%) followed by Maldives (9.2%) according to the
2015 estimate by IDF [1]. Obesity is the main culprit
which is most prevalent in this region [5].
Pakistan has an estimated 6.9 million people affected
with diabetes according to IDF and this number is
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expected to increase to 14.4 million by the year 2040 [1].
South Asians are more likely to develop type 2 diabetes
mellitus (T2DM) at younger ages and at lower BMI than
other races [2, 6]. People in the SA region have more
visceral adiposity which increases their risk compared to
Caucasians [7]. Visceral obesity which is associated with
insulin resistance is metabolically unfavorable and con-
tributes to lipotoxicity [8].
Despite the efforts to control morbidity and mortality
associated with the disease, the rate of chronic compli-
cations, remain high [9]. According to previous studies,
the reported prevalence of macro vascular diseases like
cardiovascular disease (CAD), peripheral vascular dis-
ease (PVD) and cerebrovascular disease (CVD) is
27.2%. In addition to it, the prevalence of micro vascu-
lar manifestations of chronic hyperglycemia including
retinopathy, nephropathy and diabetic foot ulcers is
53.5% [10]. Complications of diabetes are related to
chronic hyperglycemia represented by high HbA1c
levels. Therefore, HbA1c goals are established in vari-
ous parts of the world to control the complications of
diabetes mellitus. The American Diabetes Association,
International Diabetes Federation, Canadian Diabetes
Association and Diabetes Australia recognize an HbA1c
level of 7% although most recognize that goals need to
be set according to individual circumstances [11]. The
American Association of Clinical Endocrinologist,
Korean and Malaysian guidelines consider 6.5% or less
[12, 13]. There are various studies which have used dif-
ferent cut-offs of HbA1c levels to report prevalence of
uncontrolled diabetes mellitus (UDM) at various ter-
tiary care centers in Pakistan but the quality of data is
questionable and does not reflect the general popula-
tion. Khowaja et al using a cut-off level of ≥7.4%
reported a prevalence of 51.6% of UDM in 2010 [14]
while a recent study done at community based special-
ized care center at district central Karachi in 2014 re-
ported prevalence of UDM of 39% using HbA1c cut-off
level of ≥8% [15].
The metabolic and genetic profile of our population
subset puts it at increased risk for certain complications
compared to others [16]. There is a need to collect more
accurate and uniform data regarding control and com-
plications of diabetes in Pakistani population. Hospital
based diabetes registries have been recognized as an im-
portant tool to evaluate the clinical course, outcome and
complications of diabetes and to identify the high risk
groups [17]. We established a diabetes registry in an out-
patient setting for the patients attending diabetes clinic
at a large tertiary care hospital in the city of Karachi
which has an ethnically diverse population exceeding 25
million people. Our center is catering to the people
belonging to different socioeconomic groups from the
city and surrounding areas.
The aim of setting up a registry is to document char-
acteristic and pattern of diabetes mellitus in our patient
population. This registry was also set up to help physi-
cians to monitor trends in care processes, risk factors,
indicators and complications over time. The aim of the
current study is to assess the patterns, control levels and
complications at the baseline of the patients attending
clinic with the help of the registry and this information
can be used later on to measure the progress.
Methods
Study design and settings
This was a cross-sectional study with data obtained from
a diabetes registry based in a large tertiary care hospital
located in Karachi, Pakistan. The Aga Khan University
(AKU) is a private tertiary care teaching hospital cater-
ing to the needs of population of Karachi and surround-
ing areas. It is accredited by the Joint Commission
International. A diabetes registry has been established at
the endocrinology clinics, AKU since 2014. It collects
real time information on a predesigned form on all pa-
tients with diabetes mellitus patients presenting to the
clinics. The protocol of the study was reviewed and
given an exemption by The Aga Khan University Ethics
Review Committee (ERC). Due to the retrospective na-
ture of the study based on the guidelines by ERC, the
need to take informed consent was waived. In addition,
it is usually conveyed to patients at the time of their visit
that the information regarding their health could be
used for research purpose. The information was not col-
lected on any personal identifiers. The files were
accessed at the time of clinic visit so no additional
permission was required.
Selection of participants
This study captured all patients diagnosed with diabetes
mellitus and presenting to the study site between 22nd
September 2014 and 31st July 2015 for the first time.
The data was collected retrospectively.
Data collection procedures
A physician trained in data collection reviewed all med-
ical record charts at the diabetes & endocrinology
clinics, and entered data in the diabetes registry.
Random checks were done by the investigators of the
project to ensure integrity and accuracy of data
collection.
The questionnaire (Additional file 1) used in registry
consisted of five different sections; (i) Demographics and
initial assessment (ii) medications (iii) Comorbid condi-
tions/complications (iv) Physical examination (v)
Laboratory data (vi) Management plan. It collects infor-
mation on age, gender, BMI, smoking history, comorbid
conditions, and years since diagnosis, current
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medications, micro and macro vascular complications
and lab data was entered. Any undocumented informa-
tion was referred back to physician who saw the patient
during visit.
At the clinics, weight (kg) and height (cm) are mea-
sured using mechanical scales. The limits for BMI were
taken according to Asian specific cut off highlighted by
World Health Organization. The categories suggested
for Asians are: less than 18.5 kg/m2 (underweight);
18.5–23 kg/m2 (normal); 23–27.5 kg/m2 (overweight)
and 27.5 kg/m2 or higher (obesity). Blood pressure (BP)
is checked using mercury sphygmomanometer or digital
scale while patient is in sitting position and arm at the
level of heart. All measurements are done as a part of
initial assessment by trained nurses. A repeat blood
pressure is checked by the doctor when patient goes
inside the clinic for the assessment. All instruments
undergo standard maintenance procedures at regular
intervals as part of institutional quality assurance.
Outcomes
On target/optimum glycemic control was the primary
outcome of this study and was defined as HbA1c either
less than or equal to 7.0. On target BP was defined as
blood pressure <140/90. LDL was said to be on target if
it was <100, combine target was defined as on target
LDL, BP and HbA1c.
Statistical analyses
Statistical analysis was carried out using statistical pack-
age for social sciences (SPSS, version 19.0). Mean with
SD were reported for all quantitative variables with nor-
mal distribution such as age and frequency with percent-
ages were reported for all categorical variables such as
gender, smoking status, type of diabetes, comorbid con-
ditions, complications etc. Chi-square test was used to
explore characteristics across groups with on target
HbA1c, BP and LDL. Independent sample T-test was
used to compare quantitative variables such as Age,
HbA1c etc. across categories. Logistic regression analysis
was used to explore factors associated with optimum
glycemic control (HbA1c ≤ 7.0). Crude ORs along with
95% Confidence intervals (CI) were calculated. Variables
with a P-value ≤ 0.25 or biologically plausible associa-
tions were selected for multivariate logistic regression
analysis. Adjusted ORs along with their 95% CIs were
calculated from multivariate logistic regression model.
All potential confounders and interactions were evalu-
ated. A P-value of <0.05 was considered as statistically
significant for multivariable model.
Results
During study period, a total of 876 patients presented to
Diabetes clinic for an initial visit with mean age of 53.1
± 11.9 years. There were approximately equal number of
male and female patients and majority were 36 years and
above. Three fourth of the study population were obese
according to Asian specific BMI cutoffs with duration of
diabetes ranging from less than one to about 35 years,
mean(SD) duration being 7.6 years (7.1). Only 16.6% of
the participants had optimal HbA1c ≤ 7.0%. 52.9% of the
patients were classified as having poor control defined
by HbA1c of >8%. About 42.2% of the participants had
BP (either systolic HTN >140 or diastolic >90 or both).
More than half of the participants (58.7%) whose
Vitamin-D levels were evaluated had a deficiency (≤20).
Nephropathy, depression and diabetic foot were pre-
sented in 13.8, 6.3 and 1.6% patients respectively. About
7.4% of men gave history of erectile dysfunction. Eye
examination revealed background and proliferative dia-
betic retinopathy (DR) in 6.5 and 1.3% respectively.
About 13.4% were reported to have peripheral neur-
opathy and 1.4% had peripheral vascular disease.
Table 1 shows characteristics of the study partici-
pants stratified by age groups. An increasing trend was
observed in percentage of obesity with age with a de-
cline seen in participants with ages older than 55 years
(P < 0.001). A higher percentage of patients in the age
group 36-54 years had triglycerides more than or equal
to 150 however in the later age this percentage is seen
to be reduced (P = 0.003). Likewise, a higher number of
participants in younger age group had higher LDL
levels and a reducing trend was observed with increas-
ing age (P = 0.01). Metabolic controls and BMI of study
participants according to age categories are shown in
Figs. 1 and 2.
A majority (59.5%) of the patients were on oral anti
diabetic agents (OAD) alone, followed by 22.2% on com-
bination therapy of OAD plus insulin, 10.8% on insulin
alone and 7.6% of the participants were not on any
pharmacotherapy for diabetes. About 7% of the partici-
pants were on treatment for neuropathy, 39.1% were on
antiplatelet treatment, 40.1% on statins or other lipid
lowering drugs and 52.6% on antihypertensive. A major-
ity of patients receiving treatment for secondary preven-
tion were > 55 years of age (Table 2). About 68.9% of
patients were on metformin, 39.6% were on DPP4,
40.5% were on sulfonylureas, 3.8% were on glitazones,
and 0.6% were on acarbose. About 255 patients were on
one OAD, 292 were on 2, 160 were on 3 and 7 patients
were on 4 OAD.
As compared to men, a higher percentage of women
were obese (77.7% vs. 85.6%, p = 0.01) with longer dia-
betes duration (48.0% vs. 54.2%, P = 0.06), known his-
tory of hypertension (50.0% vs. 61.5%, p = 0.001),
depression (3.5% vs. 9.3%, p < 0.001), elevated total
cholesterol (18.6% vs. 26.9%, p = 0.04), elevated BP at
clinic visit (38.3% vs. 46.4%) and low HDL levels
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(55.3% vs. 72.7%, p < 0.001). However, a higher percentage
of men had elevated triglyceride levels i.e. ≥ 150(56.8% vs.
41.2%, p = 0.001), coronary artery disease (17.4 vs. 8.8,
p < 0.001) and nephropathy (17.4 vs. 10.0, p = 0.001).
Vitamin D deficiency was observed in about 66.7% of
men as compared to 53.7% women (p = 0.04). There
was no statistically significant difference in HbA1c
alone or combine target of HbA1c, LDL and BP based
on gender.
About 56% of the patients had on target LDL levels on
initial visit. Those having on target LDL levels were sig-
nificantly older, with longer duration of diabetes and had
lower HbA1c. Most of the participants with on target
LDL levels were on lipid lowering (61.8%),
Table 1 Demographic and clinical characteristics of initial patients presenting to diabetes clinics at AKU
Variables Overall <18 years old 18-35 years old 36-54 years old ≥55 years old P-value
n = 876 n = 3 n = 61 n = 396 n = 416
Gender, n (%) 0.78
Male 454(51.8) 1(33.3) 34(55.7) 208(52.5) 211(50.7)
Female 422(48.2) 2(66.7) 27(44.3) 188(47.5) 205(49.3)
BMI, mean ± SD 29.6(5.6) 23.4(4.7) 29.9(6.7) 30.5(5.5) 28.7(5.2) <0.001
Smoking status, n (%) <0.001
Current smoker 85(9.8) 0(0) 6(9.8) 53(13.5) 26(6.3)
Ex-smoker 81(9.3) 0(0) 3(4.9) 21(5.3) 57(13.8)
Non-smoker 705(80.9) 3(100) 52(85.2) 319(81.2) 331(80.0)
Duration of Diabetes, n (%) <0.001
≤ 5 years 424(49.0) 2(66.7) 48(78.7) 240(60.9) 134(32.9)
6-10 207(23.9) 1(33.3) 6(9.8) 91(23.1) 109(26.8)
11-15 126(14.6) 0(0) 4(6.6) 42(10.7) 80(19.7)
16-20 62(7.2) 0(0) 2(3.3) 16(4.1) 44(10.8)
21-25 27(3.1) 0(0) 1(1.6) 4(1.0) 22(5.4)
26-30 15(1.7) 0(0) 0(0) 1(0.3) 14(3.4)
31-35 4(0.5) 0(0) 0(0) 0(0) 4(1.0)
Comorbid conditions, n (%)
Known HTN 486(55.5) 1(33.3) 18(29.5) 178(44.9) 289(69.6) <0.001
Known Dyslipidemia 361(41.3) 0(0) 14(23.0) 158(39.9) 189(45.5) 0.003
Known CAD 116(13.3) 0(0) 0(0) 24(6.1) 92(22.2) <0.001
HbA1c, mean ± SD 8.6(2.2) 11.3(2.4) 8.7(2.3) 8.7(2.1) 8.5(2.1) 0.17
LDL (mg/dl), n (%) 0.015
< 100 251(56.0) 0(0) 9(40.9) 102(50.2) 140(63.1)
≥ 100(high) 197(44.0) 1(100) 13(59.1) 101(49.8) 82(36.9)
HDL (mg/dl), n (%)
Female
0.31
≥ 50(normal) 50(27.3) 0(0) 1(10.0) 18(23.7) 31(32.3)
< 50(low) 133(72.7) 1(100) 9(90.0) 58(76.3) 65(67.7)
Male
< 40(low) 119(55.3) 0(0) 7(70.0) 63(58.9) 49(50.0) 0.28
≥ 40(normal) 96(44.7) 0(0) 3(30.0) 44(41.1) 49(50.0)
Triglyceride (mg/dl), n (%) 0.003
< 150(acceptable) 218(50.3) 0(0) 10(47.6) 81(41.3) 127(59.1)
≥ 150(high) 215(49.7) 1(100) 11(52.4) 115(58.7) 88(40.9)
BP (mmHg), n (%) <0.001
On Target(<140/90) 505(57.8) 3(100) 34(55.7) 256(64.6) 212(51.2)
High(either >140 or 90 or both) 369(42.2) 0(0) 27(44.3) 140(35.4) 202(48.8)
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antihypertensive (65.3%) and antiplatelet (51.8%) drugs.
About 58.5% of participants had on target BP. Patients
with on target BP were younger, more likely to be males
and with shorter duration of diabetes. A higher percent-
age of patients with elevated BP had peripheral
neuropathy as well.
Overall only 4% of the patients were on combine
target of HbA1c, LDL and BP. Those on target were sig-
nificantly older with mean age 57.7 ± 13.8 vs. 52.8 ± 11.8,
had acceptable total cholesterol (96.8% vs. 76.0%), LDL
(100% vs. 52.3%) and triglyceride (75.8% vs. 48.3%) levels
as compared to those not on target. About 71.4% of the
patients who were on target were on lipid lowering
agents, 82.9% were on OHA alone followed by 11.4% on
no anti diabetics, 2.9% on insulin alone and 2.9% on
combine OHA plus insulin. Gender, BMI, duration of
diabetes, comorbid conditions and HDL levels were not
significantly different across the categories.
About 23.9% of the patients had optimal glycemic con-
trol (HbA1c ≤ 7.0) on initial visit. Patients with optimal
control were significantly older, with shorter duration of
diabetes and lower percentage of known coronary artery
disease as compared to patients with suboptimal
glycemic control. A higher number of participants with
suboptimal HbA1c also had elevated SGPT and triglycer-
ides. A higher percentage of patients with optimal
glycemic control were on OHA alone (71.7% vs. 54.7%)
or not on any hypoglycemic agents (15.9% vs. 5.0%) and
a lower percentage of these patients were on insulin
alone (4.8% vs. 13.2%) and a combination of insulin and
OHA (7.6 vs. 27.1) as compared to those with subopti-
mal control (Table 3).
Fig. 1 BMI levels by Age categories of initial patients presenting to diabetes
Fig. 2 Percentage of participants having on target HbA1c on initial visit
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Factors associated with optimal glycemic control were
examined using logistic regression models. On univariate
level, Age (OR = 1.02; 95% CI = 1.00-1.03), higher duration
of diabetes(OR = 0.51; 95% CI = 0.35-0.75), coronary artery
disease (OR = 0.45; 95% CI = 0.24-0.86), higher SGPT
levels(OR = 0.48; 95% CI = 0.24-0.97), higher triglyceride
levels (OR = 0.65; 95% CI = 0.40-1.0), use of hypoglycemic
agents(Insulin alone: OR = 0.11;95% CI = 0.04-0.30, OHA
alone: OR = 0.41; 95% CI = 0.22-0.76, Combine insulin and
OHA: OR = 0.08; 95% CI = 0.03-0.20) and presence of
complications(OR = 0.60; 95% CI = 0.39-0.90) were found
to be significantly associated with optimal glycemic con-
trol. In the multivariable model Age, duration of diabetes
and triglyceride levels were associated with good glycemic
control. After adjusting for other covariates, with every
one year increase in age, the odds of having optimal
glycemic control increased by 3%. Having duration of
diabetes more than 5 years was associated with 56% lower
chances of having good glycemic control. Higher triglycer-
ides were associated with 1% lower odds of having good
glycemic control. There was no confounding and
interaction in the model (Table 4).
Discussion
This study describes the baseline HbA1c in relation to
certain clinical parameters of the patients presenting to
the specialized diabetic clinic at tertiary care hospital in
the large cosmopolitan city of Pakistan. The mean
HbA1c was 8.6 ± 2.2% with duration of 7.6 ± 7.1 years
and only 17% of the patients achieved glycemic goal of
<7%,optimal target defined by ADA. This highlights
the large burden of sub optimally controlled people
with diabetes in our population causing enormous
health care and economic burden. The mean HbA1c
achieved is nearly comparable to the data reported pre-
viously from low and middle income countries of Asia
and Middle East.
Poor glycemic control was associated with younger
age, longer duration of diabetes and high triglyceride
levels.
Overall, 58.7% of diabetics had insufficient vitamin D
levels. The association of poor glycemic control with
vitamin D deficiency has been controversial [18–20].
Based on our registry, no association was found
between glycemic control and Vitamin D levels.
In terms of treatment of T2 DM, majority of the in-
dividuals were on oral anti diabetic agents and 16%
were not on any form of treatment. On further ana-
lysis, 55% of diabetics on oral anti diabetic agents
alone and 13.2% on once basal daily dose with OAD
had suboptimal glycemic control. This can be attrib-
uted to the phenomenon of “clinical inertia” due to
delivery of care by non-specialist and certain myths
and misconceptions of the population regarding insu-
lin treatment. The soaring and skyrocketing prices for
insulin which has tripled between 2002 and 2013 could
be another reason for the delay in treatment.
Macro vascular disease in the form of coronary heart
disease, a primary cause of death in diabetes was found
to be present in 13% of the individuals. Both micro and
Table 2 Treatment data of initial patients presenting to diabetes clinics at AKU
Variables Overall <18 years old 18-35years old 36-54years old ≥55 years old P-value
n = 876 n = 3 n = 61 n = 396 n = 416
Treatment, n (%) <0.002
Insulin alone 94(10.8) 2(66.7) 5(8.3) 32(8.1) 55(13.3)
OHA alone 520(59.5) 1(33.3) 33(55.0) 260(65.7) 226(54.5)
Combine OHA and Insulin 194(22.2) 0(0) 15(25.0) 73(18.4) 106(25.5)
Neither OHA nor Insulin 66(7.6) 0(0) 7(11.7) 31(7.8) 28(6.7)
Lipid lowering agents (statins, fibrates, ezitimibe), n (%)
Yes 351(40.1) 0(0) 7(11.5) 141(35.6) 203(48.8) <0.001
No 525(59.9) 3(100) 54(88.5) 255(64.4) 213(51.2)
Antihypertensive Agents, n (%) <0.001
Yes 461(52.6) 1(33.3) 15(24.6) 175(44.2) 270(64.9)
No 415(47.4) 2(66.7) 46(75.4) 221(55.8) 146(35.1)
Antiplatelet, n (%) <0.001
Yes 342(39.1) 0(0) 8(13.3) 108(27.3) 226(54.3)
No 532(60.9) 3(100) 52(86.7) 287(72.7) 190(45.7)
Pregablin/ gabapentin, n (%) 0.19
Yes 61(7.0) 0(0) 3(5.0) 21(5.3) 37(8.9)
No 812(93.0) 3(100) 57(95.0) 374(94.7) 378(91.1)
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Table 3 Factors associated with Glycemic control in patients presenting for an initial visit at AKU (n = 606)
Characteristics Optimal Glycemic control
HbA1c ≤7.0
145(23.9)
Suboptimal glycemic control
HbA1c 7.1 and above
461(76.1%)
P-values
Age 55.9(12.8) 52.8(11.4) 0.007
Gender 0.50
Male 74(51.0) 250(54.2)
Female 71(49.0) 211(45.8)
BMI 0.61
Underweight/acceptable(<18.5 -22.9) 14(10.1) 33(7.5)
Overweight(23-24.9) 14(10.1) 46(10.5)
Pre-obese and Obese(25 and above) 110(79.7) 360(82.0)
Smoking status 0.33
Current smoker 15(10.3) 44(9.6)
Ex-smoker 9(6.2) 47(10.3)
Non-smoker 121(83.4) 367(80.1)
Duration of Diabetes, mean(SD) 0.01
≤ 5 years 85(59.9) 199(43.5)
6-10 years 32(22.5) 107(23.4)
11-15 years 16(11.3) 76(16.6)
16-20 years 4(2.8) 44(9.6)
21-25 years 3(2.1) 18(3.9)
26-30 years 2(1.4) 9(2.0)
31-35 years 0(0) 4(0.9)
Comorbid Conditions
Known HTN 84(57.9) 269(58.4) 0.92
Known Dyslipidemia 61(42.1) 206(44.7) 0.58
Known CAD 12(8.3) 76(16.5) 0.01
Complications
Nephropathy 20(13.8) 86(18.7) 0.17
Depression 14(9.7) 30(6.5) 0.41
Diabetic foot 2(1.4) 10(2.2) 0.28
Amputation 1(0.7) 4(0.9) 0.37
Creatinine 0.69
< 1.5 114(93.4) 371(94.4)
≥ 1.5 8(6.6) 22(5.6)
SGPT 0.03
Normal(≤45 male, ≤35 female) 51(81.0) 143(67.5)
High(>45 male, >35 female) 12(19.0) 69(32.5)
Total Cholesterol 0.37
≤ 200 (normal) 73(82.0) 207(77.5)
> 200 (high) 16(18.0) 60(22.5)
HDL 0.11
Low(<50 for females, <40 for males) 48(54.5) 166(64.1)
Normal(≥50 for females, ≥40 for males) 40(45.5) 93(35.9)
LDL 0.17
< 100 62(63.9) 165(56.1)
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Table 3 Factors associated with Glycemic control in patients presenting for an initial visit at AKU (n = 606) (Continued)
≥ 100(high) 35(36.1) 129(43.9)
Triglyceride 0.09
< 150(acceptable) 54(59.3) 140(48.8)
≥ 150(high) 37(40.7) 147(51.2)
Vit B-12 0.35
< 150(deficient) 0(0) 3(6.4)
150-201 2(10.0) 8(17.0)
> 201(acceptable) 18(90.0) 36(76.6)
Vit D 0.03
≤ 20.9(deficient) 11(40.7) 44(68.8)
21-29.9(insufficient) 7(25.9) 6(9.4)
30-150(sufficient) 9(33.3) 14(21.9)
Urine Microalbumin 0.009
< 19(normal) 38(76.0) 69(54.8)
≥ 19(high) 12(24.0) 57(45.2)
Blood pressure 0.74
On Target(<140/90) 83(57.2) 271(58.8)
High(either >140 or 90 or both) 62(42.8) 190(41.2)
Fundoscopy
Background DR 1(1.1) 24(7.8) 0.02
Proliferative DR 0(0) 4(1.3) 0.28
Foot Exam
Peripheral neuropathy 13(10.4) 53(13.2) 0.41
Peripheral vascular disease 0(0) 10(2.5) 0.07
Treatment <0.001
Insulin alone 7(4.8) 61(13.2)
OHA alone 104(71.7) 252(54.7)
Combine OHA and Insulin 11(7.6) 125(27.1)
Neither OHA nor Insulin 23(15.9) 23(5.0)
Lipid lowering agents(Statins, Fibrates, Ezitimibe) 0.40
Yes 61(42.1) 212(46.0)
No 84(57.9) 249(54.0)
Anti-hypertensive 0.71
Yes 83(57.2) 256(55.5)
No 62(42.8) 205(44.5)
Anti-platelets 0.15
Yes 52(35.9) 196(42.5)
No 93(64.1) 265(57.5)
Pre-gabalin 0.79
Yes 10(6.9) 35(7.6)
No 134(93.1) 426(92.4)
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macro vascular diseases were more in patients with poor
glycemic control.
This study also highlights the increasing prevalence
of obesity in Pakistani population since two third of
the patients presenting to diabetes clinic were obese
based on south Asian targets of BMI. The majority of
these obese individuals were in the middle age group
(36-55 years of age) which increases the tendency to
develop diabetes, HTN and lipid abnormalities in the
most productive years of one’s life posing economic
burden both at individual and societal level. The high
BMI in majority of the individuals could also be the
reason of not finding the association between poor
glycemic control and BMI.
All the patients with poor glycemic control also had
uncontrolled BP and lipid profile displaying the overall
treatment inadequacy & paucity of control of other mea-
sures. Interestingly patients achieving optimal glycemic
control did not meet the targets for lipid and blood pres-
sure recommended by ADA. This was further shown to
be mainly because of the underuse of medications for
the control of lipids and BP since 62% of patients with
dyslipidemia were not using any anti lipid medications.
Likewise 40% of the hypertensive patients were not tak-
ing any anti-hypertensive treatment. This finding is of
significant concern since these are the conventional
modifiable risk factors which if not controlled can give
rise to early onset of coronary heart disease and the risk
is more in South Asians compared to Caucasians. The
reasons could be multifactorial. It could be because of
financial constraints since patient has to pay out of their
pocket for these medications. The other reason could be
the lack of adherence of the physicians to the treatment
guidelines.
This study was limited by the fact that the data was
acquired from the review of the charts completed by
doctors at different levels. There are some factors which
were not probably documented accurately like history of
smoking which was noted down as positive in a minority
of patients. Some of the complication data was based on
the history and physical finding which could include
some subjectivity.
Our registry has several strengths. First the data repre-
sents baseline characteristics of patients with diabetes
from a large and diverse population belonging to differ-
ent ethnic groups and socioeconomic levels. This is one
of the few diabetes registries in Pakistan that would
monitor the metabolic disease on regular basis.
With increasing prevalence of diabetes, the care pro-
vided at the basic primary level needs to be improved
since majority of the individuals cannot bear cost of
complications. Government and different non-
governmental organizations should invest in polyclinics
in different areas to provide cost effective care to dia-
betics. Indicators of quality care (HbA1c & other com-
plications) should be assessed regularly for better
diabetes management. Moreover patient registries
should be used nationwide to improve the quality of the
care provided to diabetic individuals.
Conclusion
This registry confirms that large proportion of diabetic
population do not achieve optimal level of glycemic con-
trol. In addition to the glycemic targets, the other pa-
rameters were also found to be not at target which can
increase the risk of diabetic complications.
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